Omnicell (NASDAQ:OMCL) Given New $38.00 Price Target at Wells Fargo & Company

Omnicell (NASDAQ:OMCL - Free Report) had its target price lowered by Wells Fargo & Company from $40.00 to $38.00 in a report issued on Thursday,Benzinga reports. The firm currently has an equal weight rating on the stock.

Several other research analysts also recently weighed in on OMCL. JPMorgan Chase & Co. cut their price target on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Bank of America lowered their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Benchmark restated a "buy" rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Finally, StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, April 15th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Omnicell presently has a consensus rating of "Hold" and an average price target of $50.67.

Omnicell Stock Performance

Omnicell stock traded up $0.27 during mid-day trading on Thursday, reaching $29.92. 641,816 shares of the company were exchanged, compared to its average volume of 534,562. The firm's 50-day simple moving average is $35.06 and its two-hundred day simple moving average is $41.18. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.75. The firm has a market cap of $1.40 billion, a PE ratio of 110.82, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC raised its holdings in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after buying an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the fourth quarter worth $37,000. Van ECK Associates Corp boosted its position in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares during the period. Headlands Technologies LLC purchased a new position in shares of Omnicell during the fourth quarter valued at $53,000. Finally, First Horizon Advisors Inc. raised its position in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.